K
Kazuhisa Yoshimura
Researcher at Kumamoto University
Publications - 4
Citations - 136
Kazuhisa Yoshimura is an academic researcher from Kumamoto University. The author has contributed to research in topics: Nucleoside & Virus. The author has an hindex of 2, co-authored 4 publications receiving 82 citations. Previous affiliations of Kazuhisa Yoshimura include Fukushima Medical University.
Papers
More filters
Journal ArticleDOI
Syntheses of 4‘-C-Ethynyl-β-d-arabino- and 4‘-C-Ethynyl-2‘-deoxy-β-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity
Hiroshi Ohrui,Satoru Kohgo,Kenji Kitano,Sakata Shinji,Eiichi Kodama,Kazuhisa Yoshimura,Masao Matsuoka,Shiro Shigeta,Hiroaki Mitsuya +8 more
TL;DR: In this article, 4'-C-ethynyl-2'-deoxy-ribo derivatives were synthesized by radical reduction of 2'-bromo or 2'- phenoxythiocarbonyloxy nucleosides.
Journal ArticleDOI
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: In this article, the authors examined the effect of BNT162b2-elicited SARS-CoV-2 neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants and the potency of sera against variants of concerns.
Posted ContentDOI
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.